The Download: weight-loss drugs slowing aging and carbon dioxide batteries

Not long ago, that sounded like a fantasy. Weight-loss drugs slowing aging? Today, two of the largest pharmaceutical companies on Earth are making exactly that claim about their GLP-1 medications, and they're doing it openly, which is a remarkable turn for a field that once treated such an idea as little more than a longevity researcher's dream, and it's a claim we've now got to take seriously.

Eli Lilly and Novo Nordisk say their GLP-1 drugs slow aging. That's the claim. Patients taking these drugs age less quickly, measured against molecular "aging clocks" that track changes in DNA or levels of key proteins, according to the two companies. And the findings feed growing speculation that GLP-1 drugs could be acting on basic causes of aging and might turn out to be true longevity treatments, though it's not proven yet and we can't say they're a cure for aging itself.

But there is a catch.

The open question is how much anyone should read into these results. Aging clocks remain an unsettled science. They are statistical readouts, not a direct measurement of lifespan. The drugmakers are excited, and that excitement is worth paying attention to, but excitement is not evidence.

What the Aging Clocks Actually Show

An aging clock works by reading chemical markers that shift as the body gets older. Some track changes in DNA. Others follow shifts in levels of key proteins. When the clock says a person is aging slowly, it means those markers look younger than expected for someone at that chronological age.

The drugmakers say their patients show exactly that pattern. If that holds up under scrutiny, the idea of weight-loss drugs slowing aging would move from intriguing possibility to medical reality.

Why These Results Deserve Caution

Here's the awkward part. A slower aging clock isn't the same as living longer. A drug could shift biomarkers. It might not add a single year of life. And the speculation is exciting, but the cause-and-effect chain, which so many people badly want to see closed once and for all, has not been nailed down.

• Eli Lilly and Novo Nordisk both report aging-clock signals in patients taking their GLP-1 drugs.
• The molecular clocks track changes in DNA or levels of key proteins.
• The findings add to speculation that GLP-1 drugs act on basic causes of aging.
• The open question remains how much to read into these early results.

Let's break this down. If the drugs help people lose weight, and weight loss improves everything from blood pressure to inflammation, then a slower aging clock might simply be reflecting better overall health. Whether the drugs touch aging itself is a separate question. That distinction is the difference between a health improvement and a longevity treatment.

It's a huge story. Weight-loss drugs slowing aging would be one of the biggest medical stories of the decade, a claim so large that it would reshape how we think about medicine, aging, and the daily pills people take. But the history of medicine is full of promising biomarkers that failed to deliver. The burden of proof here is high. And we've seen this before.

A Battery Built on Compressed Carbon Dioxide

Solar and wind are among the cheapest and quickest ways to add electricity to the grid. But they are subject to variations in weather patterns, which means supplies can be intermittent. Energy Dome, one of the ten climate tech companies worth watching this year, has an unusual fix: massive batteries that use compressed carbon dioxide to store energy for when the grid needs it.

Compressing gas to store energy isn't new. Utilities have used compressed air in underground caverns to hang on to reserves for decades. But Energy Dome's approach is different. And it matters.

Why Geology Has Held This Idea Back

Traditional compressed-air storage needs specific geology. A sealed cavern, a salt dome, something underground and airtight. Energy Dome's system does not require any of that, which means it could be scaled more easily and help grids around the world without waiting for the right rocks.

The promise is straightforward: a storage technology that fits where grids actually need it, not just where the geology happens to cooperate.

AlphaGo's Lesson for Today's AI

Ten years ago, a program called AlphaGo beat Go champion Lee Sedol, and the decisive move was so strange that some commentators thought it was a programming glitch. It was not a glitch. Thore Graepel, a core member of DeepMind's AlphaGo team, says it was AlphaGo's powers of reasoning that made that creative choice.

And those powers, he argues, are precisely what today's AI lacks.

The observation lands at a sensitive moment. Large language models are being sold as reasoning machines, and the gap between that pitch and what they actually do is growing. Graepel's essay on the subject is now available as a narrated podcast on Spotify and Apple Podcasts.

One Man's Natural Intelligence

Not everyone wants the latest AI-powered hardware. Mike Tyran, a 66-year-old nurse and self-described tech upgrade holdout, has a term for what he already has.

I have 'NI',natural intelligence. I'm good with that.

His refusal to swap old gadgets for the newest AI-powered devices is a small counterweight to the industry's assumption that newer always wins.

The Rest of the Tech Headlines

OpenAI's 377 Math Problems

OpenAI released 377 new math findings. They're spread across number theory, algebra, geometry, and physics, and they came from testing an unreleased OpenAI model, a process that cost far less than the company's previous math breakthroughs. OpenAI also published a lengthy defense of its approach. And that's a sign. The company knows the field is watching closely, so it's clearly aware that people don't miss much, and that every claim gets checked.

A Trillion-Parameter Model and Other Moves

Mistral says its new open-weight model, Mistral Large 4, is the best outside China. It packs one trillion parameters. Its weights arrive October 27. And French president Macron called it "a third way in AI," a phrase that lands with unusual weight because this model, which Mistral claims stands as the best outside China and which carries one trillion parameters with weights set to arrive on October 27, is being framed by Macron as something other than the usual binary.

Finland has ordered Google to halt a record data center project, citing environmental concerns. The 13 billion euro project is Google's largest-ever European investment. Meanwhile, the European Union plans to tax Big Tech through a new corporate levy aimed at companies earning more than 100 million euros. Tesla is separately pushing the EU toward approval of its "Full Self-Driving" system.

Anduril's 2.9 billion dollar Navy submarine deal has sparked ethics concerns, particularly after co-founder Palmer Luckey joined a new Pentagon project. The company is also making smart glasses for warfare.

Apple is partnering with LG on a smart lock, thermostat, and doorbell, with a smart-home hub expected to launch next week. The two companies are also co-developing security cameras.

Chips Made of Glass

Human-made glass is thousands of years old. But it's now poised to find its way into the AI chips used in the world's newest and largest data centers, which is a shift that few people saw coming. This year, a South Korean company called Absolics will start producing special glass panels that make next-generation computing hardware more powerful and efficient. Other companies, including Intel, are also pushing forward in this area. So the race is on. If all goes well, the technology could reduce the energy demands of chips in AI data centers, and even in consumer laptops and mobile devices.

Small Wins Worth Noticing

Amid all the trillion-parameter models and billion-euro deals, a few stories land differently. Swiss researchers have turned train tracks into solar power plants. That's not a small thing. A teenager with a rare genetic disorder walked for the first time after receiving an experimental medicine, a moment that no benchmark or balance sheet could ever capture. Photographers captured stunning shots of guillemots, penguins, and a protective tawny frogmouth for the Bird Photographer of the Year competition. And they're beautiful.

Weight-loss drugs slowing aging will keep making headlines, and the skeptics will keep asking for harder evidence. Carbon dioxide batteries will need to prove they scale. AI reasoning claims will face the same scrutiny. The technology moves fast. The proof takes longer.